Cwm, LLC Arbutus Biopharma Corp Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Cwm, LLC holds 2,500 shares of ABUS stock, worth $8,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,500

Previous 2,339 6.88%

Holding current value

$8,650

Previous $7,000 42.86%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$3.12 - $4.56 $502 - $734	161 Added 6.88%	2,500 $10,000
Q2 2024 Jul 09, 2024	BUY	$2.52 - $3.63 $1,617 - $2,330	642 Added 37.83%	2,339 $7,000
Q1 2024 Apr 05, 2024	BUY	$2.26 - $2.92 $3,512 - $4,537	1,554 Added 1086.71%	1,697 $4,000
Q4 2023 Feb 01, 2024	BUY	$1.69 - $2.54 $224 - $337	133 Added 1330.0%	143 $0
Q3 2020 Sep 15, 2021	BUY	$1.75 - $6.2 $17 - $62	10 New	10 $0
Q3 2020 Oct 19, 2020	SELL	$1.75 - $6.2 $17 - $62	-10 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$0.91 - $2.36 $9 - $23	10 New	10 $0
Q2 2020 Jul 22, 2020	SELL	$0.91 - $2.36 $9 - $23	-10 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$1.01 - $3.42 $10 - $34	10 New	10 $0
Q1 2020 Apr 28, 2020	SELL	$1.01 - $3.42 $10 - $34	-10 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$0.87 - $2.89 $8 - $28	10 New	10 $0
Q4 2019 Jan 27, 2020	SELL	$0.87 - $2.89 $8 - $28	-10 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$1.34 - $2.4 $13 - $24	10 New	10 $0
Q3 2019 Oct 22, 2019	SELL	$1.34 - $2.4 $13 - $24	-10 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$1.46 - $4.44 $14 - $44	10 New	10 $0
Q2 2019 Jul 31, 2019	SELL	$1.46 - $4.44 $14 - $44	-10 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$3.41 - $4.57 $34 - $45	10 New	10 $0

Others Institutions Holding ABUS

# of Institutions

156

Shares Held

99.6M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $519M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account